Literature DB >> 8198612

Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine.

R Z Pino1, M Feelisch.   

Abstract

Nitroxyl (NO-) is the one-electron reduction product of nitric oxide (NO.). Recently, NO- generating compounds were shown to possess potent vasorelaxant activity and this was attributed to the ready conversion of NO- to NO.. Because of its metastable character, direct chemical detection of NO- or its conjugated acid, HNO, has not been accomplished yet. In order to gain further insight into the cellular mode of action of NO- generating compounds we aimed at finding a means to discriminate NO- from NO. by bioassay. Using isolated rat aortic rings in organ baths, we here show that high concentrations of L-cysteine cause complete inhibition of the vasorelaxant response to NO- (generated from Angeli's salt and sodium nitroxyl) whereas responses to authentic NO. and S-nitrosocysteine are largely enhanced. Preliminary results indicate that the inhibition by L-cysteine of NO- activity may be mediated in part by enzymatic and non-enzymatic mechanisms. Whether or not NO- generating compounds will have promising therapeutic potential as a new class of NO.- donors will not least depend on their interference with enzymatic routes susceptible to inhibition by NO-.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198612     DOI: 10.1006/bbrc.1994.1668

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

1.  Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle.

Authors:  C G Li; J Karagiannis; M J Rand
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Nitroxyl gets to the heart of the matter.

Authors:  Martin Feelisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

Review 3.  NO and the vasculature: where does it come from and what does it do?

Authors:  Karen L Andrews; Chris R Triggle; Anthie Ellis
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

4.  A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Authors:  Kathryn H Yuill; Polina Yarova; Barbara K Kemp-Harper; Christopher J Garland; Kim A Dora
Journal:  Antioxid Redox Signal       Date:  2010-10-07       Impact factor: 8.401

Review 5.  The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO.

Authors:  Nazareno Paolocci; Matthew I Jackson; Brenda E Lopez; Katrina Miranda; Carlo G Tocchetti; David A Wink; Adrian J Hobbs; Jon M Fukuto
Journal:  Pharmacol Ther       Date:  2006-11-29       Impact factor: 12.310

6.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

7.  Oxidation of nitroxyl anion to nitric oxide by copper ions.

Authors:  S Nelli; M Hillen; K Buyukafsar; W Martin
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 8.  The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems.

Authors:  Wilmarie Flores-Santana; Debra J Salmon; Sonia Donzelli; Christopher H Switzer; Debashree Basudhar; Lisa Ridnour; Robert Cheng; Sharon A Glynn; Nazareno Paolocci; Jon M Fukuto; Katrina M Miranda; David A Wink
Journal:  Antioxid Redox Signal       Date:  2011-03-16       Impact factor: 8.401

9.  A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase.

Authors:  Karen L Andrews; John J McGuire; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 10.  Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.

Authors:  Barbara K Kemp-Harper; John D Horowitz; Rebecca H Ritchie
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.